{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-023497","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2022-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.242425+00:00","generated_at":"2026-06-25T00:46:27.939929+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Lyra Therapeutics stockholders elect three Class II directors and ratify auditor at annual meeting","bullets":["Michael Altman, C. Ann Merrifield, and Harlan Waksal elected as Class II directors with votes for 19.7M-19.8M each; 2.5M broker non-votes.","Ratification of BDO USA as independent auditor for FY2022: 22.3M for, 25.5K against, 16.5K abstained.","Approximately 70.19% of outstanding shares (22.3M of ~31.8M) represented at the meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-023497","json":"https://secwatch.observer/filing/0001564590-22-023497.json","markdown":"https://secwatch.observer/filing/0001564590-22-023497.md","text":"https://secwatch.observer/filing/0001564590-22-023497.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000156459022023497/0001564590-22-023497-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000156459022023497/lyra-8k_20220616.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T00:46:27.939929+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}